超越肿瘤:放射性标记成纤维细胞活化蛋白抑制剂(FAPI)在非肿瘤性分子影像中的作用
本综述阐述放射性标记FAPI在非肿瘤性疾病中的应用,涵盖其作用机制、放射性标记技术、药代动力学与生物分布,并分析FAPI-PET和SPECT在心血管疾病、肝纤维化、肺纤维化、肾脏疾病、骨关节疾病及其他炎症性疾病中的诊断性能,与常规影像比较优劣,最后讨论标准化、验证研究及定量影像生物标志物开发等挑战与未来方向。
要点
- FAPI可可视化并定量成纤维细胞活化,适用于以纤维化、炎症和组织重塑为特征的非肿瘤性疾病。
- 综述涵盖心血管、肝、肺、肾、骨关节及炎症性疾病等多系统非肿瘤应用。
- FAPI影像的诊断性能需与常规影像技术比较,并需标准化与验证研究支持临床转化。
核心结论
- FAPI成像在非肿瘤性疾病中具有改善诊断、治疗规划和监测的潜力,但需标准化、验证研究及定量影像生物标志物开发以提升临床效用。
研究设计与样本
- 综述,检索范围与纳入文献原文未报告。
关键影像表现/征象
- FAPI成像可显示并定量成纤维细胞活化,这一过程见于纤维化、炎症和组织重塑等多种病理状态。
- 综述分析了FAPI-PET和SPECT在心血管疾病(心肌梗死、动脉粥样硬化、心肌病、心脏淀粉样变性、系统性血管炎)、肝纤维化、肺纤维化(特发性肺纤维化及其他间质性肺病)、肾脏疾病(慢性肾脏病、狼疮性肾炎、IgA肾病)、骨关节疾病(类风湿关节炎、银屑病关节炎、假体周围关节感染及其他骨关节病变)及炎症性疾病(克罗恩病、IgG4相关性疾病)中的应用。
局限性
- 原文指出该领域面临标准化、验证研究及定量影像生物标志物开发等挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Radiolabeled fibroblast activation protein inhibitors (FAPIs) have emerged as promising tracers for molecular imaging, particularly in the field of oncology. However, their potential extends beyond cancer applications to a wide range of non-oncological conditions characterized by fibrosis, inflammation, and tissue remodeling. This review addresses the expanding role of FAPI-based imaging in non-malignant diseases, related to its ability to visualize and quantify fibroblast activation, a key process in various pathological conditions. We discuss the mechanism of action of FAPIs, their radiolabeling techniques, and their pharmacokinetics and biodistribution. The review then delves into the evidence supporting the use of FAPI-PET and SPECT in specific non-oncological applications, including cardiovascular diseases (myocardial infarction, atherosclerosis, cardiomyopathies, cardiac amyloidosis, and systemic vasculitis), liver fibrosis, pulmonary fibrosis (idiopathic pulmonary fibrosis and other interstitial lung diseases), renal diseases (chronic kidney disease, lupus nephritis, and IgA nephropathy), bone and joint diseases (rheumatoid arthritis, psoriatic arthritis, periprosthetic joint infection, and other bone and joint pathologies), and other inflammatory conditions (Crohn's disease and IgG4-related disease). We analyze the diagnostic performance of FAPI imaging in these conditions, comparing it with conventional imaging techniques and highlighting its advantages and limitations. Finally, we discuss the challenges and future directions in the field, including the need for standardization, validation studies, and the development of quantitative imaging biomarkers to improve the clinical utility of FAPI-based imaging in non-oncological applications. The aim of this review is to provide a comprehensive overview of the current state of FAPI imaging in non-oncological diseases, highlighting its potential to improve diagnosis, treatment planning, and monitoring of these conditions.
引用
- Jafari E, Juweid ME, Bahtouee M, et al. Beyond Cancer: The Role of Radiolabeled Fibroblast Activation Protein Inhibitors (FAPI) in Non-Oncological Molecular Imaging. Acad Radiol. 2025. PMID: 40753024. doi:10.1016/j.acra.2025.07.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。